In the same year, Elkotamy and co-workers designed and synthesized a series of pyrazolo[1,5-a]pyrimidine derivatives bearing zinc-binding groups to achieve dual inhibition of tumor-associated carbonic anhydrase isoforms IX and XII, as well as cyclin-dependent kinase 6 (CDK6), targeting critical pathways in non-small-cell lung cancer (NSCLC) [53]. The gene discussed is CDK6; the disease is non-small cell lung carcinoma.